Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837238 · ClinicalTrials.gov registry record · NA
Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients
A NA study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT01837238: Completed NA study, sponsored by University of Illinois at Urbana-Champaign.
NCT01837238 is a NA study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01837238, a NA study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.
Primary Outcome
Lean mass will be assessed via DXA at baseline and after 6 months of HMB supplementation.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT HMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-05 |
| Phase | NA |
What the finished NCT01837238 record still lists
NCT01837238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01837238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01837238 about?
NCT01837238 is a clinical study titled "Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients". The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.
What is the current status of trial NCT01837238?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2012-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01837238?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), HMB (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01837238?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01837238's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia